Takeda Pharmaceutical Co - ADR (TAK) Company Profile & Statistics

Takeda Pharmaceutical Co - ADR
TAK
(NYSE)
N/A
13.36
+0.09 (+0.68%)
in:usd•As of: May 03, 2024 15:59 UTC -4
Open
13.37
High
13.40
Low
13.31

About Takeda Pharmaceutical Co - ADR

CEO

Christophe Weber

Headquarters

1-1, nihonbashi-honcho 2-chome, chuo-ku

tokyo, m0 103-8668, japan

Auditor

KPMG AZSA LLC

Employees

49,095

Share Holders

346

Website

www.takeda.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

Takeda Pharmaceutical Co - ADR Statistics

Valuation Measures

Market Capitalization ²	42.28B
Enterprise Value	72.04B
Enterprise Value/EBITDA (ttm)	9.86
Price to Earnings Ratio (ttm)	6.86
Price to Book (mrq)	0.92
Price to Sales (ttm)	1.44
Price to Cash (ytd)	3.73

Profitability

Gross Margin (ttm)	67.55%
Operating Margin (ttm)	20.55%
Profit Margin (ttm)	4.18%
Return on Equity (ttm)	12.57%
Return on Invested Capital (ttm)	1.66%
Return on Assets (ttm)	5.89%

Income Statement

Revenue (ttm)	29.79B
Revenue Per Share (ttm)	N/A
Gross Profit (ttm)	20.13B
EBITDA (ttm)³	7.30B
Net Income Avi to Common (ttm)	1.29B
Diluted EPS (ttm)	0.66

Share Statistics

Beta (5Y Monthly)	0.56
52-Week Change	-19.19%
S&P500 52-Week Change	26.43%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	N/A
Dividend Yield	3.91%
Float ⁴	3.16B
% Held by Insiders	0.04%
% Held by Institutions	9.17%

Balance Sheet

Total Cash (mrq)	2.16B
Total Cash Per Share (mrq)	N/A
Total Debt (mrq)	31.72B
Total Debt/Equity (mrq)	69.17%
Current Ratio (mrq)	1.06%
Quick Ratio (mrq)	0.55%
Book Value Per Share (mrq)	14.49

Cash Flow

Operating Cash Flow Per Share (ytd)	0.94
Free Cash Flow (ytd)	2.15B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Takeda Pharmaceutical Co - ADR

Trade With A Regulated Broker